The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Open accessAbstract
BACKGROUND: Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a multicenter, randomized trial comparing four treatment groups consisting of a combination chemotherapy regimen of two different intensities followed by involved-field radiation therapy at two different dose levels. METHODS: We randomly assigned 1370 patients with newly diagnosed early-stage Hodgkin's lymphoma with a favorable prognosis to one of four treatment groups: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of radiation therapy (group 1), four cycles of ABVD followed by 20 Gy of radiation therapy (group 2), two cycles of ABVD followed by 30 Gy of radiation therapy (group 3), or two cycles of ABVD followed by 20 Gy of radiation therapy (group 4). The primary end point was freedom from treatment failure; secondary end points included efficacy and toxicity of treatment. RESULTS: The two chemotherapy regimens did not differ significantly with respect to freedom from treatment failure (P=0.39) or overall survival (P=0.61). At 5 years, the rates of freedom from treatment failure were 93.0% (95% confidence interval [CI], 90.5 to 94.8) with the four-cycle ABVD regimen and 91.1% (95% CI, 88.3 to 93.2) with the two-cycle regimen. When the effects of 20-Gy and 30-Gy doses of radiation therapy were compared, there were also no significant differences in freedom from treatment failure (P=1.00) or overall survival (P=0.61). Adverse events and acute toxic effects of treatment were most common in the patients who received four cycles of ABVD and 30 Gy of radiation therapy (group 1). CONCLUSIONS: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy. Long-term effects of these treatments have not yet been fully assessed. (Funded by the Deutsche Krebshilfe and the Swiss Federal Government; ClinicalTrials.gov number, NCT00265018.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Self-citationGallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Dühmke, E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.023 · Cited by 460
Self-citationChemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064601 · Cited by 450
van Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Ng, A. K., Bernardo, M. P., Weller, E., Backstrand, K. H., Silver, B., Marcus, K. C., Tarbell, N. J., Friedberg, J., Canellos, G. P., & Mauch, P. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.021 · Cited by 422
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., Burns, B. F., Winter, J. N., Horning, S. J., Dar, A. R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.085 · Cited by 323
Specht, L., Gray, R. G., Clarke, M. J., & Peto, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.830 · Cited by 239
Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W. H., Zijlstra, J. M., Bockisch, A., et al. (2008) · Blood · doi:10.1182/blood-2008-06-155820 · Cited by 204
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Self-citationSpecht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.005 · Cited by 582
Self-citationAndré, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6394 · Cited by 542
Hodgkin lymphoma: A review and update on recent progress
Shanbhag, S., & Ambinder, R. F. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21438 · Cited by 481
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Engert, A., André, M., Federico, M., Illidge, T., Hutchings, M., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu181 · Cited by 474
Self-citationHodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Aleman, B. M. P., André, M., Federico, M., Hutchings, M., Illidge, T., Engert, A., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy080 · Cited by 431
Self-citationABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., Horning, S. J., Dar, A. R., Shustik, C., Stewart, D. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111961 · Cited by 406
Raemaekers, J. M. M., André, M. P. E., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., Brice, P., Fermé, C., van der Maazen, R., Gotti, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.9298 · Cited by 387
Steidl, C., Connors, J. M., & Gascoyne, R. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8401 · Cited by 374
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Radiation induced secondary malignancies: a review article
Dracham, C. B., Shankar, A., & Madan, R. (2018) · Radiation Oncology Journal · doi:10.3857/roj.2018.00290 · Cited by 349
Wang, C.-M., Wu, Z.-Q., Wang, Y., Guo, Y.-L., Dai, H.-R., Wang, X.-H., Li, X., Zhang, Y.-J., Zhang, W.-Y., Chen, M.-X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332
Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Wood, M. E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P., & Travis, L. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8681 · Cited by 323
von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5807 · Cited by 314
Self-citationEl-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bøgsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4036 · Cited by 295
Küppers, R., Engert, A., & Hansmann, M.-L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61245 · Cited by 286
Self-citationAetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Wahnefried, W. D., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 264
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Self-citationChiaravalloti, A., Danieli, R., Abbatiello, P., Di Pietro, B., Travascio, L., Cantonetti, M., Guazzaroni, M., Orlacchio, A., Simonetti, G., & Schillaci, O. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2703-0 · Cited by 43
Metadata
- Authors
- Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., Debus, J., Eble, M. J., Sökler, M., Ho, A., Rank, A., Ganser, A., Trümper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Král, Z., Fuchs, M., Müller-Hermelink, H.-K., Müller, R.-P., & Diehl, V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-12
- Volume
- 363
- Issue
- 7
- Pages
- 640-652
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140801657
- Cited by
- 928
- References
- 14
- FWCI
- 41.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.